Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.
2.

Low amount of salinomycin greatly increases Akt activation, but reduces activated p70S6K levels.

Kim JH, Choi AR, Kim YK, Kim HS, Yoon S.

Int J Mol Sci. 2013 Aug 22;14(9):17304-18. doi: 10.3390/ijms140917304.

3.

Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.

Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX.

Mol Cancer Ther. 2013 Aug;12(8):1665-75. doi: 10.1158/1535-7163.MCT-13-0159. Epub 2013 May 20.

4.

MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.

Lu JW, Lin YM, Lai YL, Chen CY, Hu CY, Tien HF, Ou DL, Lin LI.

Med Oncol. 2015 Jul;32(7):206. doi: 10.1007/s12032-015-0650-7. Epub 2015 Jun 19.

PMID:
26087957
5.

Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.

Pant A, Lee II, Lu Z, Rueda BR, Schink J, Kim JJ.

PLoS One. 2012;7(7):e41593. doi: 10.1371/journal.pone.0041593. Epub 2012 Jul 24.

6.
7.

Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.

Somnay Y, Simon K, Harrison AD, Kunnimalaiyaan S, Chen H, Kunnimalaiyaan M.

Anticancer Drugs. 2013 Jan;24(1):66-72. doi: 10.1097/CAD.0b013e3283584f75. Erratum in: Anticancer Drugs. 2013 Jul;24(6):658.

8.

Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.

Zhao YY, Tian Y, Zhang J, Xu F, Yang YP, Huang Y, Zhao HY, Zhang JW, Xue C, Lam MH, Yan L, Hu ZH, Dinglin XX, Zhang L.

Drug Des Devel Ther. 2014 Oct 10;8:1827-37. doi: 10.2147/DDDT.S67961. eCollection 2014.

9.

Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer.

Agarwal E, Chaudhuri A, Leiphrakpam PD, Haferbier KL, Brattain MG, Chowdhury S.

BMC Cancer. 2014 Mar 1;14:145. doi: 10.1186/1471-2407-14-145.

10.

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.

Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H.

Mol Cancer Ther. 2010 Jul;9(7):1956-67. doi: 10.1158/1535-7163.MCT-09-1012. Epub 2010 Jun 22.

11.

Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.

Ramakrishnan V, Kimlinger T, Haug J, Painuly U, Wellik L, Halling T, Rajkumar SV, Kumar S.

PLoS One. 2012;7(11):e50005. doi: 10.1371/journal.pone.0050005. Epub 2012 Nov 21.

12.

MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death.

Jiao P, Zhou YS, Yang JX, Zhao YL, Liu QQ, Yuan C, Wang FZ.

Mol Cell Biochem. 2013 Oct;382(1-2):217-24.

PMID:
23797319
13.

Co-treatment of Salinomycin Sensitizes AZD5363-treated Cancer Cells Through Increased Apoptosis.

Choi AR, Jung MJ, Kim JH, Yoon S.

Anticancer Res. 2015 Sep;35(9):4741-7.

PMID:
26254364
14.

Salinomycin inhibits Akt/NF-κB and induces apoptosis in cisplatin resistant ovarian cancer cells.

Parajuli B, Lee HG, Kwon SH, Cha SD, Shin SJ, Lee GH, Bae I, Cho CH.

Cancer Epidemiol. 2013 Aug;37(4):512-7. doi: 10.1016/j.canep.2013.02.008. Epub 2013 Mar 29.

PMID:
23545383
15.

The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.

Lin YH, Chen BY, Lai WT, Wu SF, Guh JH, Cheng AL, Hsu LC.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Jan;388(1):19-31. doi: 10.1007/s00210-014-1032-y. Epub 2014 Aug 28.

PMID:
25164962
16.

Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein.

Kim JH, Chae M, Kim WK, Kim YJ, Kang HS, Kim HS, Yoon S.

Br J Pharmacol. 2011 Feb;162(3):773-84. doi: 10.1111/j.1476-5381.2010.01089.x.

17.

Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling.

Kim N, Kim CH, Ahn DW, Lee KS, Cho SJ, Park JH, Lee MK, Kim JS, Jung HC, Song IS.

J Gastroenterol Hepatol. 2009 Mar;24(3):480-7. doi: 10.1111/j.1440-1746.2008.05599.x. Epub 2008 Sep 24.

PMID:
18823436
18.

Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest.

Kim JH, Yoo HI, Kang HS, Ro J, Yoon S.

Biochem Biophys Res Commun. 2012 Feb 3;418(1):98-103. doi: 10.1016/j.bbrc.2011.12.141. Epub 2012 Jan 5.

PMID:
22244892
19.

Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab.

Iida M, Brand TM, Campbell DA, Starr MM, Luthar N, Traynor AM, Wheeler DL.

Cancer Biol Ther. 2013 Jun;14(6):481-91. doi: 10.4161/cbt.24342.

20.

Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.

De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N.

Neoplasia. 2014 Jan;16(1):43-72. Erratum in: Neoplasia. 2014 Apr;16(4):375. Neoplasia. 2014 Apr;16(4):375.

Items per page

Supplemental Content

Write to the Help Desk